Analysts' Top 5 Price Targets of July 24, 2025
Reading Time: 3 minutes
AxoGen Inc. [US05463X1063] Lake Street reaffirms Buy rating with a price target of $30 (123% upside potential) AxoGen specializes in surgical solutions for the repair and regeneration of peripheral nerves – an area of growing clinical importance. A key argument for the positive assessment is the new growth strategy under CEO Mike Dale. The new company leader aims to establish AxoGen as the standard therapy in the market for peripheral nerve repairs – a market estimated by analysts to have a volume of around $5.6 billion. Deutsche Telekom...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
